PATENT CLAIM ANALYSIS

Application Number: 15863746
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["514", "424000"]

Abstract:
Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Claim (Index 1):
A method of administering a pharmaceutical composition to a human patient, comprising administering to said human patient orally, once daily, a therapeutically effective dose of said pharmaceutical composition, wherein said pharmaceutical composition comprises:\n (i) a drug, wherein the drug is lacosamide or a pharmaceutically acceptable salt thereof; and (ii) at least one excipient, wherein at least one of said at least one excipient modifies the release of said drug to provide an extended release form; and wherein said pharmaceutical composition has a dissolution profile characterized by three or more of the following:\n (a) less than 10% release at 1 hour, \n (b) less than 15% release at 2 hours, \n (c) less than 25% release at 4 hours, \n (d) at least 35% release at 9 hours, \n (e) at least 65% at 12 hours, \n wherein said dissolution is carried out in 900 mL simulated gastric fluid (pH 1.2) at 37\u00b10.5\u00b0 C. for the first two hours, followed by 900 mL simulated intestinal fluid (pH 6.8) at 37\u00b10.5\u00b0 C. for the subsequent four hours, followed by 900 mL phosphate buffer (pH 7.5) at 37\u00b10.5\u00b0 C. for the subsequent 18 hours, wherein all dissolution is performed in a USP Apparatus 1 (Basket), with a rotational speed of 100 rpm; and \n wherein said pharmaceutical composition has a plasma concentration profile for said drug characterized by a T max  of 8 to 20 hours as determined by dosing said pharmaceutical composition to a subject of a fasted, single dose, human pharmacokinetic study.

Metadata:
- Claim Count in Document: 81.0
- Percentile: 86.0
- Lexical Diversity: 1.70968
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15428980', '15430084', '15428878', '15428899', '12959321']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7762022575076206
- 35 USC 102 Novelty (BERT): 0.5475564724045582
- Combined Prediction Score: 0.7533376789973144
- Mean Citation Score: 399.386666
- Max Citation Score: 422.99954
- Similarity Product: 304.21640948347687

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test